Cellosaurus J82 (CVCL_0359)

Cell line name J82
Synonyms J-82; J 82; J82COT; J82 COT
Accession CVCL_0359
Resource Identification Initiative To cite this cell line use: J82 (RRID:CVCL_0359)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).
Part of: UBC-40 urothelial bladder cancer cell line index.
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: TP53 p.Glu271Lys (PubMed=9850064).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_8240 (Hu609); CVCL_4V98 (J82-NVB)
Originate from same individual CVCL_5H97 ! J82-EBV
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; KCLB; PubMed=11416159

Markers:
AmelogeninX,Y
CSF1PO10,11
D13S31710,12
D16S53911,12
D18S5112
D21S1130,31
D3S135816,18
D5S81812,13
D7S8209,11
D8S11798,13
FGA20,24
TH019.3
TPOX11,12
vWA17,18
Web pages http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/j/cell-lines-detail-250.html
Publications

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=864752; DOI=10.1093/jnci/58.6.1743
Marshall C.J., Franks L.M., Carbonell A.W.
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.
J. Natl. Cancer Inst. 58:1743-1751(1977)

PubMed=870558; DOI=10.1177/25.4.870558
Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.
Alkaline phosphatase activity in human bladder tumor cell lines.
J. Histochem. Cytochem. 25:266-274(1977)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6823318; DOI=10.1038/301429a0
O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.
Identity of some human bladder cancer cell lines.
Nature 301:429-430(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=3413074; DOI=10.1073/pnas.85.16.604
Pereira-Smith O.M., Smith J.R.
Genetic analysis of indefinite division in human cells: identification of four complementation groups.
Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3
Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Cancer Genet. Cytogenet. 135:139-146(2002)

PubMed=14762065; DOI=10.1101/gr.2012304
Bignell G.R., Huang J., Greshock J., Watt S., Butler A., West S., Grigorova M., Jones K.W., Wei W., Stratton M.R., Futreal P.A., Weber B., Shapero M.H., Wooster R.
High-resolution analysis of DNA copy number using oligonucleotide microarrays.
Genome Res. 14:287-295(2004)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; HTB-1
KCB; KCB 2014052YJ
KCLB; 30001
Cell line databases/resources CCLE; J82_URINARY_TRACT
CCRID; 3111C0001CCC000346
CCRID; 3131C0001001200024
Cosmic-CLP; 753566
GDSC; 753566
IGRhCellID; J82
LINCS_LDP; LCL-1714
Ontologies BTO; BTO:0001671
CLO; CLO_0007006
EFO; EFO_0002210
MCCL; MCC:0000253
Biological sample resources BioSample; SAMN03471085
Chemistry resources ChEMBL-Cells; CHEMBL3308508
ChEMBL-Targets; CHEMBL614586
Gene expression databases GEO; GSM492491
GEO; GSM827204
GEO; GSM887167
GEO; GSM888239
GEO; GSM1374575
GEO; GSM1574579
GEO; GSM1669946
Polymorphism and mutation databases Cosmic; 753566
Cosmic; 755399
Cosmic; 760474
Cosmic; 808517
Cosmic; 809378
Cosmic; 845571
Cosmic; 846276
Cosmic; 867838
Cosmic; 943731
Cosmic; 1016887
Cosmic; 1046674
Cosmic; 1093984
Cosmic; 1175827
Cosmic; 1285119
Cosmic; 1285996
Cosmic; 1302362
Cosmic; 1927308
Cosmic; 1995459
Cosmic; 2050445
Cosmic; 2057450
Cosmic; 2444229